the canada-eu smart living environments addressing transitions in care for ageing people is expected to:

• develop and implement smart living environments that address transitions in care challenges for ageing people through acceptable information and communications technology (ict)-based solutions;
• improve health outcomes, patient experience, effectiveness, and lower the cost of care within one (1) or more of the identified research areas related to ageing people through identifying, evaluating and implementing acceptable, evidence-based and effective smart living environments;
• build novel multi-disciplinary and trans-disciplinary collaborations and partnerships with individuals and organizations in canada and in the eu that have interest in transformative research in care transitions by promoting engagement, recognition and respect for health research expertise across an array of health disciplines, research pillars, and industry; and
• demonstrate the capability to progress beyond prototype stage for smart living environment solutions into a care delivery program(s) for pragmatic evaluation.

the fy20 defense appropriations act provides funding to the department of defense melanoma research program (mrp) to support innovative, high-impact melanoma research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 mrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

applications for the idea award, translational research award, team science award, and the mid-career accelerator award submitted to the fy20 mrp must address one or more of the following focus areas:

• prevention of melanoma initiation factors (e.g., uv radiation)
• prevention of melanomagenesis and precursor lesions (e.g., novel genetic and epigenetic drivers, oncogene induced senescence)
• understanding the tumor microenvironment

○       primary tumor

○       regional nodes

○       distal nodes

• bioengineering (e.g., computational, imaging) approaches to address diagnostics, high risk markers, dormancy, and metastasis
• therapeutic prevention (e.g., interruption of disease progression, recurrence)

• minimal residual disease (e.g., chemoprevention, micro-metastasis)

applications for the technology development partnership award submitted to the fy20 mrp must address the focus area: bioengineering (e.g., computational, imaging) approaches to address diagnostics, high risk markers, dormancy, and metastasis.

the mrp challenges the research community to redefine the concept of prevention and has issued afy20 mrp challenge statement  that should be considered when responding to the fy20 mrp focus areas and funding opportunities.

the mrp encourages studies for rare melanomas across the entire spectrum from initiation to distant macro-metastasis.

https://cdmrp.army.mil/funding/mrp 

idea award – preproposal due june 22, 2020

independent investigators with a faculty-level appointment (or equivalent)

• preproposal is required; application submission is by invitation only.
• supports new ideas that represent innovative, high-risk/high-gain approaches to melanoma research.
• emphasis on innovation and impact.
• must address at least one of the fy20 focus areas.
• preliminary data are not required.
• clinical trials are not allowed.
• maximum funding of $300,000 for direct costs (plus indirect costs)
• maximum period of performance is 3 years

mid-career accelerator award –preproposal due june 22, 2020

assistant or associate professors more than 7 years post-first faculty appointment.

instructors and full professors are not eligible

• preproposal is required; application submission is by invitation only.
• supports mid-career researchers to conduct impactful melanoma research.
• must address at least one of the fy20 focus areas.
• must show evidence of at least one peer reviewed extramural funding award.
• preliminary data is required.
• clinical trials are not allowed.
• maximum funding of $700,000 for direct costs (plus indirect costs)
• maximum period of performance is 3 years

team science award – preproposal due june 22, 2020

at least two and up to three investigators must partner in one overarching multidisciplinary research study.

initiating principal investigator:

independent investigators at or above the level of associate professor (or equivalent).

inclusion of at least one military, va investigator, or early career investigator is encouraged.

• preproposal is required; application submission is by invitation only.
• supports new or existing partnerships between two or threeindependent investigators focusing research across the whole research spectrum.
• investigators are expected to demonstrate within the application, the synergistic components (i.e., leveraging disciplines, expertise or critical resources) that will significantly advance the project such that the research outcomes as a whole will be realized rapidly and efficiently and could not otherwise be accomplished through independent efforts of a single investigator.
• emphasis on synergy, multi-disciplinary research, and impact.
• must address at least one of the fy20 focus areas.
• preliminary data are required.
• clinical trials are not allowed.
  • maximum funding of $700,000 for direct costs (plus indirect costs)
  • maximum period of performance is 3 years

technology development partnership award – preproposal due june 22, 2020

two independent investigators with a faculty-level appointment (or equivalent)

• preproposal is required; application submission is by invitation only.
• supports new or existing partnerships between twoindependent investigators focusing on bioengineering approaches toaddress diagnostics, high risk markers, dormancy, and metastasis.
• one partner must have a background in biomedical science, and one must have a background in the physical sciences (e.g. engineering, computational science, bioinformatics, or computer science).m imaging) approaches to address diagnostics, high risk markers, dormancy, and metastasis.
• must address the fy20 mrp focus area: bioengineering (e.g., computational
• preliminary data is required.
• clinical trials are not allowed
• maximum funding of $700,000 for direct costs (plus indirect costs)
• maximum period of performance is 3 years

translational research award – preproposal due june 22, 2020

independent investigators at or above the level of assistant professor (or equivalent)

• preproposal is required; application submission is by invitation only.
• supports studies aiming to leverage existing biobanks, biorepositories, ongoing or completed clinical trialsto address a translational question or problem in melanoma.
• emphasis on translation and impact.
• must address at least one of the fy20 focus areas.
• preliminary data is required.
• clinical trials are not allowed.
  • maximum funding of $600,000 for direct costs (plus indirect costs)
  • maximum period of performance is 3 years

translational research award – collaborator option – preproposal due june 22, 2020

two independent investigators at or above the level of assistant professor (or equivalent)

• preproposal is required; application submission is by invitation only.
• supports two investigators in a joint study aiming to leverage existing biobanks, biorepositories, ongoing or completed clinical trialsto address a translational question or problem in melanoma.
• emphasis on translation and impact.
• must address at least one of the fy20 focus areas.
• preliminary data is required.
• clinical trials are not allowed.
  • maximum funding of $700,000 for direct costs (plus indirect costs)
  • maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org .  for more information about the mrp or other cdmrp-administered programs, please visit the cdmrp website http://cdmrp.army.mil 

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

the fy20 defense appropriations act has provided funding to the department of defense tuberous sclerosis complex research program (tscrp) to support innovative, high-impact tsc research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

fy20 congressional appropriation for tscrp funding, fy20 tscrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

applications submitted to the fy20 tscrp are encouraged to address one or more of the following focus areas:

• eradicating tumors associated with tsc and tsc-associated lymphangioleiomyomatosis (lam), including gaining a deeper mechanistic understanding of tsc signaling pathways

•       preventing epilepsy, improving treatment, and mitigating comorbidities associated with tsc-related seizures

•       understanding the features of tsc-associated neuropsychiatric disorders (tand) and reducing their impact, including pharmacological and behavioral interventions

•       advancing clinical trial readiness and optimizing clinical care through development of biomarkers and clinical outcome measures, patient selection and sample size determination, pharmacokinetic/pharmacodynamics (pk/pd) studies, and enhanced trial design

https://cdmrp.army.mil/funding/tscrp

exploration – hypothesis development award – letter of intent due june 18, 2020

investigators at all academic levels (or equivalent), including postdoctoral fellows

• supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the tsc research field.
• projects involving human subjects or human biological substances must be exempt under 32 cfr 219.101(b)(4) or eligible for expedited review under 32 cfr 219.110 or 21 cfr 56.110.
• preliminary data are not required.
• clinical trials are not allowed.
• the maximum allowable funding for the entire period of funding is $150,000 in direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 2 years

idea development award – letter of intent due june 18, 2020

established investigators: independent investigators at or above the level of assistant professor (or equivalent);

or new investigators:

independent investigator at or below the level of assistant professor (or equivalent); or

established independent investigator in an area other than tsc at or above the level of assistant professor seeking to transition to a career in tsc.

• supports ideas that have the potential to yield high-impact findings and new avenues of investigation.
• preliminary data expects.
• clinical trials not allowed.
  • new investigator option supports the continued development of promising independent investigators that are early in their faculty appointments and/or the transition or established investigators from other research fields into career in tsc research.
  • applications from new investigators and established investigators will be peer and programmatically reviewed separately.
  • the maximum allowable funding for the entire period of performance is $450,000 in direct costs.
  • indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
  • the maximum period of performance is 3 years

clinical translational research award – letter of intent due june 18, 2020

independent investigators at or above the level of assistant professor (or equivalent)

• supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including, diagnosis, prognosis, or treatment of tsc.
• studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of pk/pd are of particular interest.
• applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research.
• pilot clinical trials, including behavioral interventions, are encouraged.
• preference will be given to studies that involve human samples, patients, or leverage existing clinical data and/or ongoing clinical studies.
• preclinical studies may be appropriate but must include a clinical component.
• projects that are exploratory and/or strictly animal research will not be considered for funding.
• clinical translational potential is the most important review criterion.
• preliminary data are required.
• the maximum allowable funding for the entire period of performance is $600,000 in direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
  • the maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org/.  for more information about the tscrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

fund research projects that will address important questions regarding ethical, philosophical, legal and socio-cultural aspects related to the neurosciences and their recent advances.

special notice pertaining to the august 1, 2020 deadline

due to the covid-19 pandemic, we will not be accepting applications for engaged research grants involving face-to-face activities at the august 1, 2020 deadline.  eligible individuals seeking support for virtual engagement projects are welcome to apply.  please contact mropelewski@wennergren.org with any questions.

a wenner-gren grantee may apply for the engaged anthropology grant ($5,000 maximum) upon completion of the final reporting requirements for the dissertation fieldwork or post-ph.d. research grant.

this grant is designed to enable grantees to return to their research locale to share their research results with:

• the community  in which the research was conducted, and/or
• the academic/anthropological community in the region or country of research.

the call is open! mitacs globalink research internship (gri) is now accepting faculty submissions for summer 2021. gri pairs faculty in canada with international undergrads for 12-week research projects from may to october.
 
the globalink program builds international networks and experiences, and positions canada as a top destination for innovation and research among 世界杯2022赛程表淘汰赛 from abroad.

• all disciplines are eligible
• top-ranked senior undergrads travel from australia, brazil, china, france, germany, hong kong sar, india, mexico, tunisia, ukraine, united kingdom, and usa
• faculty can submit multiple projects and re-submit projects from previous years

submit projects by june 10, 2020, at 1 p.m. pt.

questions? visit our website or contact helpdesk@mitacs.ca.
 
mitacs recognizes that due to the pandemic and the uncertainties it’s created, you may be operating with limited ability to plan future research projects. if you feel that you cannot submit a gri proposal at this time due to the pandemic, please reach out to us at helpdesk@mitacs.ca.

in recognition of the growing importance of good governance to all canadian institutions, the canadian foundation for governance research is offering annual bertram scholarships of $15,000 each to phd 世界杯2022赛程表淘汰赛 registered at canadian universities.  the scholarship will support the work of 世界杯2022赛程表淘汰赛 who are conducting research into organisational governance as part of their doctoral research project. 

to qualify for the scholarship, the doctoral research project should focus on a topic directly related to organizational governance, including for example:

• the importance of effective boards in enabling good decision-making and improving the functioning of canadian institutions;
• governance issues of interest to canadian boards of public, private, government-agency and not-for-profit organizations;
• the role of corporate governance in enabling positive societal impacts;
• governance best practices through the canadian perspective.

the following are examples of relevant topics, although by no means an exhaustive list:

• board’s role during black swan events (e.g. pandemic, financial distress)
• diversity beyond gender
• sustainability
• oversight of corporate culture
• cybersecurity/ it governance/data governance/privacy
• the board’s role in innovation
• board understanding of political risk
• board’s role in public policy

for full details on the bertram scholarship, visit the cfgr website. the deadline for application is may 28, 2020.

the fy20 defense appropriations act provides funding to the department of defense peer reviewed medical research program (prmrp) to support to support medical research projects of clear scientific merit and direct relevance to military health.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 prmrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

the vision and mission of the prmrp is improve the health, care, and well-being of all military service members, veterans, and beneficiaries by encouraging, identifying, selecting, and managing medical research projects of clear scientific merit and direct relevance to military health.

congressionally directed topic areas:  all applications submitted to the prmrp must address at least one of the fy20 prmrp congressionally directed topic areas.  the fy20 prmrp topic areas are as follows:

• arthritis
• burn pit exposure
• chronic migraine and post-traumatic headache
• congenital heart disease
• constrictive bronchiolitis
• diabetes
• dystonia
• eating disorders
• emerging viral diseases
• endometriosis
• epidermolysis bullosa
• familial hypercholesterolemia
• fibrous dysplasia
• focal segmental glomerulosclerosis
• food allergies
• fragile x
• frontotemporal degeneration
• guillain-barré syndromemorrhage control
• hepatitis b
• hydrocephalus
• immunomonitoring of intestinal transplants
• inflammatory bowel diseases
• interstitial cystitis
• metals toxicology
• mitochondrial disease
• musculoskeletal health
• myalgic encephalomyelitis/chronic fatigue syndrome
• myotonic dystrophy
• nutrition optimization
• pancreatitis
• pathogen-inactivated blood products
• plant-based vaccines
• polycystic kidney disease
• pressure ulcers
• pulmonary fibrosis
• resilience training
• respiratory health
• rheumatoid arthritis
• sleep disorders and restriction
• spinal muscular atrophy
• sustained release drug delivery
• vascular malformations
• women’s heart disease

https://cdmrp.army.mil/funding/prmrp

clinical trial award (for emerging viral diseases and respiratory health) – letter of intent due june 8, 2020

assistant professor level or above (or equivalent)

• supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic areas of emerging viral disease and/or respiratory health.
• applications must address at least one of the focus area published in the program announcement.
• proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.
• ind or ide applications to the fda, if needed, should be submitted to the fda before the prmrp application submission deadline.
• funding limit for clinical trial not defined; requested funding must be appropriate for the scope of work proposed.
• maximum period of performance is 4 years.

investigator-initiated research award (for emerging viral diseases and respiratory health) – letter of intent is due may 28, 2020

assistant professor level or above (or equivalent)

• supports research that will make an original and important contribution to the field of research and/or patient care in the topic areas of emerging viral diseases and/or respiratory health.
• applications must address at least one of the focus areas published in the program announcement.
• partnering pi options available.
• clinical trials will not be funded.
• maximum funding of $1.6 million for direct costs (plus indirect costs); $2.0 million for direct costs (plus indirect costs) for applications including a partnering pi option
• maximum period of performance is 4 years

technology/therapeutic development award (for emerging viral diseases and respiratory health) – letter of intent due may 28, 2020

assistant professor level or above (or equivalent)

• supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of life in the topic areas of emerging viral diseases and/or respiratory health.
• applications must address at least one of the focus areas published in the program announcement.
• product-oriented (e.g., device, drug, clinical guidelines).  the product(s) to be developed may be a tangible item, such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.
• clinical trials will not be funded.
• maximum funding of $4.0 million for direct costs (plus indirect costs)
• maximum period of performance is 4 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the prmrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact: 

cdmrp help desk
301-682-5507
help@ebrap.org

the fy20 defense appropriations act provides funding to the department of defense peer reviewed medical research program (prmrp) to support to support medical research projects of clear scientific merit and direct relevance to military health.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 prmrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

the vision and mission of the prmrp is improve the health, care, and well-being of all military service members, veterans, and beneficiaries by encouraging, identifying, selecting, and managing medical research projects of clear scientific merit and direct relevance to military health.

congressionally directed topic areas:  all applications submitted to the prmrp must address at least one of the fy20 prmrp congressionally directed topic areas.  the fy20 prmrp topic areas are as follows:

• arthritis
• burn pit exposure
• chronic migraine and post-traumatic headache
• congenital heart disease
• constrictive bronchiolitis
• diabetes
• dystonia
• eating disorders
• emerging viral diseases
• endometriosis
• epidermolysis bullosa
• familial hypercholesterolemia
• fibrous dysplasia
• focal segmental glomerulosclerosis
• food allergies
• fragile x
• frontotemporal degeneration
• guillain-barré syndromemorrhage control
• hepatitis b
• hydrocephalus
• immunomonitoring of intestinal transplants
• inflammatory bowel diseases
• interstitial cystitis
• metals toxicology
• mitochondrial disease
• musculoskeletal health
• myalgic encephalomyelitis/chronic fatigue syndrome
• myotonic dystrophy
• nutrition optimization
• pancreatitis
• pathogen-inactivated blood products
• plant-based vaccines
• polycystic kidney disease
• pressure ulcers
• pulmonary fibrosis
• resilience training
• respiratory health
• rheumatoid arthritis
• sleep disorders and restriction
• spinal muscular atrophy
• sustained release drug delivery
• vascular malformations
• women’s heart disease

https://cdmrp.army.mil/funding/prmrp

clinical trial award – letter of intent due july 29, 2020

assistant professor level or above (or equivalent)

new for fy20:  optional planning phase available.  the planning phase will provide support to prepare and submit an ind/ide application to the fda; fda/regulatory approval to proceed is required prior to exercising option for clinical trial.

planning phase (optional):

maximum of $500,000 for direct costs (plus indirect costs)

maximum period of performance is 18 months

clinical trial:

no maximum funding limit; requested funding must be appropriate for the scope of work proposed.

maximum period of performance is 4 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the prmrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact: 

cdmrp help desk
301-682-5507